Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ. Cyclooxygenase-2 is overexpressed in Her-2/neu-positive breast cancer. J Biol Chem 2002; 277 :18649-18657
Kauff N, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, Norton L, Offit K. Risk-reducing salpino-oophorectomy in women with BRCA1 or BRCA2 mutations. NEJM 2002; 346 :1609-1615
Slamon DJ, Leyland-Jones B, Shak S, Fucks H, Paton V, Bajamonde A. Fleming T, Eirmann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. NEJM 2001; 344 :783-92
Norton L. Chemotherapy dose, schedule, and the modern treatment of primary breast cancer. Cancer Invest 2000; 18 :55-57
Gilewski T, Adluri S, Ragupathi G, Zhang SL, Yao TJ, Panageas K, Moynahan M, Houghton A, Norton L, Livingston PO. Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin Can Res 2000; 6 :1693-1701
Lucito R, West J, Reiner A, Alexander J, Esposito D, Mishra B, Powers S, Norton L, Wigler M. Detecting gene copy number fluctuations in tumor cells by microarray analysis of genomic representations. Genome Res 2000; 10 :1726-1736
Hazan R, Phillips GR, Ziao R, Norton L, Aaronson SA. Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion and metastasis. J Cell Biol 2000; 148 :779-790
Berry DA, Muss HB, Thor AD, Dressler L, Liu ET, Broadwater G, Budman DR, Henderson IC, Barcos M, Hayes D, Norton L. HER2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol 2000; 18 :3471-3479
Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu-overexpressing human breast cancer xenografts. Cancer Res 1999; 59 :2020
Hudis C, Fornier M, Riccio L, Lebwohl D, Crown J, Gilewski T, Subone A, Currie V, Seidman A, Reichman B, Moynahan M, Raptis G, Sklarin N, Theodoulou M, Weiselberg L, Salvaggio R, Panageas KS, Yao TJ, Norton L. Five-year results of dose-intensive sequential adjuvant chemotherapy for women with high risk node-positive breast cancer: A phase II study. J Clin Oncol 1999; 17 :1118-1126
Cummings SR, Eckert S, Kruegger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jorda VC. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation. JAMA 1999; 281 :2189-97
Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Sem Oncol 1999; 26 :78-83
Norton L. Breast cancer advocates in clinical research: A trialist's perspective. Breast Disease 1998; 10 :51-59
Norton L. A Gompertzian model of human breast cancer growth. Cancer Res 1988; 48 :7067-7071
Norton L, Simon R. Tumor size, sensitivity to therapy and the design of treatment protocols. Cancer Treat Rep 1977; 61 :1307-1317
Return to Larry Norton, MD Main Page.
